Find Relief From Depression and Anxiety With SPRAVATO (esketamine) Therapy.
Spravato is a prescription medication, used along with an antidepressant taken by mouth, for treatment-resistant depression (TRD) in adults. On March 5, 2019 the U.S. Food and Drug Administration (FDA) approved Spravato for the treatment of depression that has not responded adequately to two medication trials. Spravato is the first truly new kind of depression drug since Prozac hit the market in 1988. Spravato is a nasal spray that can relieve depression in hours instead of weeks.
Given some of the potential side effect risks patients may only seek treatment in an approved Spravato treatment center. We are the first approved treatment center in the south bay communities. Please call to arrange a consultation to review if this treatment is right for you.
What is esketamine?
Esketamine is a drug that is derived from the anesthetic ketamine that has a long history of being used to treat depression. Esketamine is a more potent form of ketamine and is fairly new to the market as it became FDA-approved in March 2019.
Esketamine treatments come in the form of a nasal spray, which has a brand name called Spravato. The nasal spray is to be used alongside antidepressants to treat more severe cases of depression that are categorized as treatment-resistant depression (TRD).
Because esketamine is considered a controlled substance, it must be administered by specially trained medical personnel in a certified clinical setting. Most patients receive it as an outpatient and go home in a couple of hours.
What does esketamine treat?
People who are currently struggling with major depressive disorder (MDD) and haven’t found success or have experienced adverse side effects from at least two different antidepressant treatments may have TRD. People with TRD may finally find success with esketamine.
What does an esketamine session look like?
SPRAVATO® PATIENT VIDEO: WHAT TO EXPECT DURING YOUR SPRAVATO® TREATMENT
Are there any side effects?
The most common side effects usually only occur within one to two hours after the nasal spray has been administered. To help ensure the safety of patients, there is a two-hour window of supervision at the clinic following the administration before patients can leave and head home. These side effects include:
TESTIMONIALS
SPRAVATO® ASK THE EXPERTS VIDEO
Doctors answer patients’ top 9 questions about SPRAVATO®. Be sure to watch the entire video to get the full SPRAVATO® story, including safety information.
DIRECT LINK: https://spravato.brightcovegallery.com/ask-the-expert
SPRAVATO® PATIENT VIDEO: NICOLE’S STORY
SPRAVATO® helped Nicole’s treatment-resistant depression. Now, she’s resuming her education and sharing her story.
DIRECT LINK: https://spravato.brightcovegallery.com/nicole-story
